GENEVA, Oct. 13 -- MERCK PATENT GMBH (Frankfurter Strasse 25064293 Darmstadt) filed a patent application (PCT/EP2025/059355) for "ANTIBODY-DRUG-CONJUGATES BINDING NAPI2B" on Apr 04, 2025. With publication no. WO/2025/210264, the details related to the patent application was published on Oct 09, 2025.
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Inventor(s): DICKGIESSER, Stephan (c/o Merck Healthcare KGaAFrankfurter Strasse 25064293 Darmstadt)
Abstract: The present invention relates to ADCs binding to NaPi2b comprising exatecan and a beta-glucuronidase cleavable linker, the ADCs being prepared by transgluta...